Analysts predict that Amarin Co. (NASDAQ:AMRN) will report earnings of ($0.06) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Amarin’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.09). Amarin reported earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The company is expected to issue its next earnings report on Wednesday, May 2nd.
On average, analysts expect that Amarin will report full-year earnings of ($0.33) per share for the current financial year, with EPS estimates ranging from ($0.44) to ($0.19). For the next financial year, analysts anticipate that the firm will report earnings of $0.11 per share, with EPS estimates ranging from ($0.05) to $0.25. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Amarin.
Amarin (NASDAQ:AMRN) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The firm had revenue of $53.87 million during the quarter, compared to analysts’ expectations of $52.73 million. The business’s revenue for the quarter was up 39.2% on a year-over-year basis. During the same period last year, the firm posted ($0.10) EPS.
In related news, General Counsel Joseph T. Kennedy sold 44,857 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total transaction of $167,316.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Joseph T. Kennedy sold 26,942 shares of the company’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $2.90, for a total value of $78,131.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 260,722 shares of company stock valued at $1,062,730. 3.72% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Paloma Partners Management Co bought a new stake in shares of Amarin during the 4th quarter worth $141,000. Hoylecohen LLC bought a new stake in shares of Amarin during the 4th quarter worth $142,000. Cubist Systematic Strategies LLC bought a new stake in shares of Amarin during the 3rd quarter worth $226,000. TD Asset Management Inc. bought a new stake in shares of Amarin during the 3rd quarter worth $285,000. Finally, Neuberger Berman Group LLC bought a new stake in shares of Amarin during the 3rd quarter worth $350,000. Institutional investors and hedge funds own 38.16% of the company’s stock.
Shares of NASDAQ:AMRN traded down $0.02 during trading on Monday, reaching $3.01. 1,353,866 shares of the company traded hands, compared to its average volume of 1,935,664. The company has a market cap of $885.72, a price-to-earnings ratio of -12.04 and a beta of 0.72. The company has a debt-to-equity ratio of -1.12, a quick ratio of 1.13 and a current ratio of 1.41. Amarin has a 52 week low of $2.82 and a 52 week high of $4.60.
Amarin Company Profile
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.